As the first Big Pharma company to deliver its fourth-quarter results on Tuesday, it was perhaps fitting that Johnson & Johnson delivered a message that will be repeated on numerous occasions over the next few weeks; exposure to generic competition is diminishing – growth from new products continues to accelerate. Prescription pharmaceutical revenues for the full year stood at $25.4 billion – versus $24.4 billion in 2011.

See on www.firstwordpharma.com